A case of pretibial myxedema treated with teprotumumab
Lauren Petit, MD +3 more
doaj +1 more source
Pathogenesis of Graves’ Ophthalmopathy [PDF]
C, Spitzweg, A E, Heufelder
openaire +2 more sources
Development of Graves orbitopathy after thyroidectomy for thyroid cancer. [PDF]
Hormiz M +5 more
europepmc +1 more source
HTLV-1-associated uveitis mimicking thyroid-associated ophthalmopathy during antithyroid therapy: a diagnostic pitfall and management challenge. [PDF]
Kasamatsu D +4 more
europepmc +1 more source
Correction: Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients. [PDF]
Wu F +5 more
europepmc +1 more source
Gypenosides attenuate H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in orbital fibroblasts from thyroid-associated ophthalmopathy by activating the Nrf2/ERK/HO-1 signaling pathway. [PDF]
Ma C +6 more
europepmc +1 more source
Triglyceride-driven pathogenesis in thyroid-associated ophthalmopathy: a dual approach of clinical correlation and genetic causality. [PDF]
Cao JM, Chen HY, Zhang F, Xiong W.
europepmc +1 more source
The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI. [PDF]
Yuan X, Li H, Wang F.
europepmc +1 more source
Euthyroid Graves' Ophthalmopathy With Negative Antibodies (EGONA): A Comprehensive Case-Based Review. [PDF]
Bonny M +6 more
europepmc +1 more source
The application value of quantitative analysis of orbital soft tissue parameters on plain CT scans in evaluating the activity of thyroid-associated ophthalmopathy. [PDF]
Ji G, Mo ZM.
europepmc +1 more source

